Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Ischemic Stroke

Overview

he purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 20, 2021

Detailed Description

In this study, 912 cases of ischemic stroke in 48 hours were included in 5 centers in China according to the principle of random, double-blind and parallel control .The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days .The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day, 7 days in a row . Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning therapy.

Interventions

  • Procedure: Remote ischemic conditioning
    • Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
  • Procedure: Sham remote ischemic conditioning
    • Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.

Arms, Groups and Cohorts

  • Active Comparator: RIC+Standard medical treatment
    • Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
  • Placebo Comparator: Sham RIC+Standard medical treatment
    • Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of patients with Modified Rankin Scale (mRS) Score 0-2
    • Time Frame: 3 months
    • The primary outcome measure of efficacy is the modified Rankin Scale (mRS) dichotomized to define good functional outcome as mRS 0-2 at 90 days.score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.

Secondary Measures

  • NIHSS Score at end of 7th day of treatment
    • Time Frame: 7 days
    • NIHSS Score at end of 7th day of treatment
  • mRS Score at end of 7th day of treatment
    • Time Frame: 7 days
    • mRS Score at end of 7th day of treatment
  • Barthel Index at end of 7th day of treatment
    • Time Frame: 7 days
    • Barthel Index at end of 7th day of treatment
  • Changes of hematological indicators
    • Time Frame: 48h; 7days
    • The changes of hematological indicators (inflammatory cytokine,et al.) between the first 48h and end of 7th day of treatment.

Participating in This Clinical Trial

Inclusion Criteria

  • 1)Age≥18 years, < 80 years, regardless of sex; – 2)Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 12 hours of stroke onset – 3)Baseline NIHSS score>5, and≤25 ; – 4)GCS score ≥8; – 5)Signed and dated informed consent is obtained Exclusion Criteria:
  • 1) Patients with suspected posterior circulation infarction; – 2) Patients who undergo thrombolytic therapy or endovascular treatment; – 3) mRS≥2 score before the onset of the disease; – 4) Double upper limbs or lower limbs paralysis was found in this case; – 5)Active bleeding of organs within 6 months of admission or current, including cerebral hemorrhage, subarachnoid hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage and so on; – 6) Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumor and other diseases involving the brain; – 7) Treated blood pressure ≤90mmHg/60mmHg or≥180mmHg/100mmHg; – 8) Severe organ dysfunction or failure; – 9) Persons suffering from severe hematological diseases or severe coagulation disorder dysfunction; – 10) Those who had a history of severe trauma or had major surgery within 6 months prior to admission; – 11) The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb;Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; – 12) Pregnant or lactating women; – 13) Previous remote ischemic conditioning therapy or similar treatment; – 14) Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons; – 15) Severe hepatic and renal dysfunction – 16) Unwilling to be followed up or treated for poor compliance; – 17) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission; – 18) Other conditions that the researchers think are not suitable for the group.
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: 80 Years

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • Yi Yang
    • Provider of Information About this Clinical Study
      • Sponsor-Investigator: Yi Yang, Clinical Trial and Research Center for Stroke – First Hospital of Jilin University
    • Overall Contact(s)
      • Yi Yang, MD, PhD, 0086-13756661217, doctor_yangyi@163.com

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.